CHICAGO—Adding cetuximab to first-line irinotecan chemotherapy for patients with metastatic colorectal cancer gave a median four months advantage in overall survival as compared with adding bevacizumab. Findings from the German Phase III FIRE study were presented at the 2013 meeting of the American Society of Clinical Oncology in Chicago by Professor Volker Heinemann from Munich University. He explained to Peter Goodwin why this research has clarified the clinical decision-making process for patients who have the non-mutated form of the KRAS gene and are thus sensitive to both of these targeted agents.
You may also like...
Low risk prostate cancer: less treatment means lower cost, and better patient outcomes 16 Mar, 2013 Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes 26 Mar, 2015 PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression 31 Oct, 2018 Preventing ER-Positive Breast Cancer—Latest from IBIS 1, 2 and 3 20 Mar, 2015
- Previous story Patients with oropharyngeal cancer: no HPV risk to spouses, partners
- Next story Heat shock protein inhibitor brings new hope in advanced pre-treated lung cancer
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014